You searched for: tocofersolan (Engelska - Maltesiska)

the active substance is tocofersolan.
is-sustanza attiva hi tocofersolan.

vedrop 50 mg/ml oral solution tocofersolan
vedrop 50 mg/ml soluzzjoni orali tocofersolan

the hydrolysis of tocofersolan occurs in the gut lumen.
l-idrolisi ta’ tocofersolan isseħħ fl-imsaren.

for tocofersolan no clinical data on exposed pregnancies are available.
għal tocofersolan m’hemmx tagħrif kliniku dwar l-użu waqt it-tqala.

vedrop contains vitamin e (in the form of tocofersolan).
vedrop fih il-vitamina e (fl-għamla ta’ tocofersolan).

the excretion of tocofersolan in milk has not been studied in animals.
l-eliminazzjoni ta’ tocofersolan fil- ħalib ma ġiex studjat fl-annimali.

it is unknown whether tocofersolan is excreted in human breast milk.
mhux magħruf jekk tocofersolan jiġix eliminat fil-ħalib tal-bniedem.

tocofersolan can be absorbed from the gut in children who have difficulty absorbing fats and vitamin e from the diet.
tocofersolan jista’ jiġi assorbit mill-imsaren fit-tfal li għandhom diffikultà jassorbu xaħmijiet u l-vitamina e mid-dieta.

the dose should be prescribed in mg of d-alpha-tocopherol in the form of tocofersolan.
id-doża għandha tiġi preskritta f’mg ta’ d-alpha-tocopherol fl-għamla ta’ tocofersolan.

a study in 12 healthy volunteers compared tocofersolan with a water-miscible reference vitamin e after a single oral loading dose of 1200 iu.
studju fi 12-il voluntier b’saħħtu qabbel tocofersolan ma’ vitamina e ta’ referenza li titħallat mal-ilma wara doża orali waħda ta’ kkargar ta’ 1200 iu.

at low concentrations, tocofersolan forms micelles which enhance absorption of non-polar lipids such as fat-soluble vitamins.
f’konċentrazzjonijiet baxxi, tocofersolan jifforma mixxelli li jqanqlu aktar l-assorbiment ta’ lipidi mhux polari bħal vitamini li jinħallu fil-grass.

each ml of solution contains 50 mg of d-alpha-tocopherol in the form of tocofersolan, corresponding to 74.5 iu of tocopherol.
kull ml ta’ soluzzjoni fiha 50 mg ta’ d-alpha-tocopherol fl-għamla ta’ tocofersolan, li tikkorispondi għal 74.5 iu ta’ tocopherol.

to support the use of vedrop, the company presented information from the scientific literature, including the results of three studies in a total of 92 children and adolescents with chronic cholestasis who were given tocofersolan for about two years.
bħala sostenn għall-użu ta’ vedrop, il-kumpanija ppreżentat informazzjoni mill-letteratura xjentifika, inklużi r-riżultati ta’ tliet studji f’total ta’ 92 tifel/tifla u adolexxenti b’kolestażi kronika konġenita jew ereditarja li ngħataw tocofersolan għal madwar sentejn.

experience with tocofersolan therapy in patients with renal impairment or underlying liver impairment has demonstrated no need to adapt the dose regimen of vedrop (see section 4.4).
l-esperjenza bit-terapija b’tocofersolan f’pazjenti b’indeboliment tal-kliewi jew indeboliment tal-fwied preżenti wriet li ma hemm ebda bżonn ta’ adattament tal-iskeda tad-dożaġġ ta’ vedrop (ara s-sezzjoni 4.4).

a decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with vedrop should be made taking into account the benefit of breast-feeding to the child and the benefit of tocofersolan therapy to the woman.
deċiżjoni jekk jitkomplix/jitwaqqafx it-treddigħ jew jekk it-terapija b’vedtop titkomplix/tieqafx għandha ssir fil-konsapevolezza tas-siwi tat-treddigħ għat-tarbija u s-siwi tat- terapija b’ tocofersolan għall-mara.